Classical Hodgkin Lymphoma in DIAPH1 Deficiency: Successful R-CHOP Therapy in a Child with Combined Immunodeficiency

Background: DIAPH1 deficiency is a rare autosomal recessive disorder characterized by seizures, cortical blindness, progressive microcephaly, and developmental delay. Emerging evidence has expanded the phenotype to include combined immunodeficiency, recurrent respiratory infections, and lymphoma. Classical Hodgkin lymphoma has only rarely been reported in association with DIAPH1 deficiency, and optimal treatment strategies remain undefined.

Case Presentation Summary: We report an 8-year-old child with genetically confirmed DIAPH1 deficiency caused by a homozygous pathogenic frameshift variant (NM_005219.4:c.2769del; p.Phe923Leufs*4). The patient exhibited infantile-onset epilepsy, progressive microcephaly, developmental delay, cortical visual impairment, recurrent otitis media and respiratory infections, bronchiectasis, combined immunodeficiency, and persistent Epstein–Barr virus (EBV) viremia (peak viral load 4.59 log10 copies/mL; latest 3.8 log10 IU/mL). At 8 years of age, the patient developed progressive bilateral cervical lymphadenopathy. Excisional lymph node biopsy with immunohistochemistry confirmed classical Hodgkin lymphoma. Staging positron emission tomography demonstrated intensely FDG-avid bilateral cervical lymphadenopathy consistent with stage II disease.

Considering the patient's underlying immunodeficiency, bronchiectasis, persistent EBV viremia, and anticipated risk of treatment-related toxicity with conventional pediatric Hodgkin lymphoma regimens, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) was selected after multidisciplinary discussion, together with immunoglobulin replacement therapy and antimicrobial prophylaxis. The patient tolerated treatment well, achieving a complete metabolic response on end-of-treatment positron emission tomography (Deauville score 3), with sustained clinical and radiological remission for 7 months following completion of therapy at the time of writing.

Learning Points Discussion: This rare case further expands the oncological spectrum of DIAPH1 deficiency by documenting classical Hodgkin lymphoma in a child with genetically confirmed disease. The coexistence of combined immunodeficiency, persistent EBV viremia, and lymphoma supports the proposed association between DIAPH1-related immune dysfunction and lymphomagenesis. Furthermore, this case demonstrates that R-CHOP, combined with comprehensive supportive care, may represent a feasible therapeutic option for carefully selected patients in whom standard pediatric Hodgkin lymphoma regimens are considered high risk. Although longer follow-up is required, this report contributes valuable clinical experience to the limited literature on malignancy and treatment outcomes in DIAPH1 deficiency.